DCM
ROIV icon

DME Capital Management’s Roivant Sciences ROIV Stock Holding History

DME Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.2M Hold
2,152,669
– – 1.95% 18
2026
Q1 		$59.6M Buy
2,152,669
+83,360
+4% +$2.14M 1.87% 18
2025
Q4 		$44.9M Sell
2,069,309
-206,220
-9% -$4.07M 1.58% 19
2025
Q3 		$34.4M Sell
2,275,529
-2,275,528
-50% -$28.2M 1.35% 20
2025
Q2 		$51.3M Sell
4,551,057
-890,110
-16% -$9.65M 2.21% 16
2025
Q1 		$54.9M Buy
5,441,167
+170,100
+3% +$1.84M 2.78% 12
2024
Q4 		$62.4M Sell
5,271,067
-36,973
-0.7% -$437K 3.21% 10
2024
Q3 		$61.3M Buy
5,308,040
+497,080
+10% +$5.66M 2.55% 11
2024
Q2 		$50.9M Buy
4,810,960
+620,470
+15% +$6.8M 2.49% 12
2024
Q1 		$44.2M Buy
+4,190,490
New +$45.2M 2.02% 16

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DME Capital Management's ROIV Position: Q2 2026 in Review

DME Capital Management held its Roivant Sciences (ROIV) position steady in Q2 2026 at 2,152,669 shares worth $76.2M. The position accounts for 1.95% of the portfolio, ranked #18.

DME Capital Management first reported a position in ROIV in Q1 2024 and has held it in 10 quarters since. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • DME Capital Management held 2,152,669 shares of Roivant Sciences worth $76.2M as of Q2 2026.
  • DME Capital Management left its Roivant Sciences share count unchanged in Q2 2026.
  • Roivant Sciences made up 1.95% of DME Capital Management's portfolio in Q2 2026, its #18 holding.
  • DME Capital Management first reported a position in Roivant Sciences in Q1 2024 and has held it in 10 quarters since.
  • 500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on DME Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.